Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 10, 2003, Pages 3104-3108

  Pea, Federico ^a   Pavan, Federica ^a   Nascimben, Ennio ^b   Benetton, Claudio ^b   Scotton, Pier Giorgio ^b   Vaglia, Alberto ^b   Furlanut, Mario ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b Regional Hospital C Foncello   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; GLUCOSE; LEVOFLOXACIN; OFLOXACIN; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; VANCOMYCIN;

ADULT; AGED; ANASTOMOSIS; AREA UNDER THE CURVE; ARTICLE; BACTERIAL MENINGITIS; BLOOD; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COHORT ANALYSIS; COMMUNICATING HYDROCEPHALUS; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISPOSITION; DRUG HALF LIFE; DRUG POTENCY; FEMALE; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROCEPHALUS; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; MALE; MICROBIOLOGY; NEUROLOGIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; STEADY STATE; STREPTOCOCCUS PNEUMONIAE;

ADULT; AGED; AREA UNDER CURVE; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSE; HALF-LIFE; HUMANS; HYDROCEPHALUS; INFUSIONS, INTRAVENOUS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; OFLOXACIN; VENTRICULOSTOMY;

EID: 0141994726     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.10.3104-3108.2003     Document Type: Article

References (37)

1. Aminimanizani, A., P. Beringer, and R. Jelliffe. 2001. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin. Pharmacokinet. 40:169-187.
2. Ball, P. 2000. Safety of the new fluoroquinolones compared with ciprofloxacin. J. Chemother. 12:8-11.
3. Blaser, J., B. B. Stone, M. C. Groner, and S. H. Zinner. 1987. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob. Agents Chemother. 31:1054-1060.
4. Burgess, D., and S. Nathisuwan. 2002. Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa. Diagn. Microbiol. Infect. Dis. 44:35.
5. Carbon, C. 2001. Comparison of side effects of levofloxacin versus other fluoroquinolones. Chemotherapy (Basel) 47(Suppl. 3):9-14.
6. Cockcroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
7. De Sarro, A., and G. De Sarro. 2001. Adverse reactions to fluoroquinolones. An overview on mechanistic aspects. Curr. Med. Chem. 8:371-384.
8. Destache, C. J., C. B. Pakiz, C. Larsen, H. Owens, and A. K. Dash. 2001. Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model. J. Antimicrob. Chemother. 47:611-615.
9. Drusano, G. L. 2000. Fluoroquinolone pharmacodynamics: prospective determination of relationships between exposure and outcome. J. Chemother. 12:21-26.
10. Fish, D. N., and A. T. Chow. 1997. The clinical pharmacokinetics of levofloxacin. Clin. Pharmacokinet. 32:101-119.
11. Flynn, C. M., D. M. Johnson, and R. N. Jones. 1996. In vitro efficacy of levofloxacin alone or in combination tested against multi-resistant Pseudomonas aeruginosa strains. J. Chemother. 8:411-415.
12. Forrest, A., D. E. Nix, C. H. Ballow, T. F. Goss, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081.
13. Hurst, M., H. M. Lamb, L. J. Scott, and D. P. Figgitt. 2002. Levofloxacin: an updated review of its use in the treatment of bacterial infections. Drugs 62:2127-2167.
14. Imanishi, T., K. Akahane, and N. Akaike. 1995. Attenuated inhibition by levofloxacin, bisomer of ofloxacin, on GABA response in the dissociated rat hippocampal neurons. Neurosci. Lett. 193:81-44.
15. Kahn, J. B. 2001. Latest industry information on the safety profile of levofloxacin in the US. Chemotherapy (Basel) 47:32-37.
16. Lacy, M. K., W. Lu, X. Xu, P. R. Tessier, D. P. Nicolau, R. Quintiliani, and C. H. Nightingale. 1999. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob. Agents Chemother. 43:672-677.
17. Lister, P. D., and C. C. Sanders. 1999. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J. Antimicrob. Chemother. 43:79-86.
18. Lister, P. D., and C. C. Sanders. 2001. Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. J. Antimicrob. Chemother. 47:811-818.
19. Lutsar, I., G. H. McCracken, Jr., and I. R. Friedland. 1998. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin. Infect. Dis. 27:1117-1127.
20. Nau, R., M. Kinzig, T. Dreyhaupt, H. Kolenda, F. Sorgel, and H. W. Prange. 1994. Kinetics of ofloxacin and its metabolites in cerebrospinal fluid after a single intravenous infusion of 400 milligrams of ofloxacin. Antimicrob. Agents Chemother. 38:1849-1853.
21. Nau, R., F. Sorgel, and H. W. Prange. 1998. Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections. Clin. Pharmacokinet. 35:223-246.
22. Nightingale, C. H., E. M. Grant, and R. Quintiliani. 2000. Pharmacodynamics and pharmacokinetics of levofloxacin. Chemotherapy (Basel) 46:6-14.
23. Ohi, Y., T. Goto, K. Kawahara, et al. 1992. Penetration of fluoro-quinolones into human spinal fluid. Chemotherapy (Tokyo) 40:469-473.
24. Ooie, T., H. Suzuki, T. Terasaki, and Y. Sugiyama. 1996. Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. Pharm. Res. 13:1065-1068.
25. Pallares, R. 1999. Treatment of pneumococcal pneumonia. Semin. Respir. Infect. 14:276-284.
26. Paris, M. M., S. M. Hickey, M. I. Uscher, S. Shelton, K. D. Olsen, and G. H. McCracken, Jr. 1994. Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob. Agents Chemother. 38:1320-1324.
27. Patel, J. A., C. T. Pachucki, and J. R. Lentino. 1993. Synergy of levofloxacin (l-ofloxacin) and oxacillin against quinolone-resistant Staphylococcus aureus, measured by the time-kill method. Antimicrob. Agents Chemother. 37:339-341.
28. Pea, F., E. Di Qual, A. Cusenza, L. Brollo, M. Baldassarre, and M. Furlanut. 2003. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. Clin. Pharmacokinet. 42:589-598.
29. Preston, S. L., G. L. Drusano, A. L. Berman, C. L. Fowler, A. T. Chow, B. Dornseif, V. Reichl, J. Natarajan, and M. Corrado. 1998. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279:125-129.
30. Preston, S. L., G. L. Drusano, A. L. Berman, C. L. Fowler, A. T. Chow, B. Dornseif, V. Reichl, J. Natarajan, F. A. Wong, and M. Corrado. 1998. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob. Agents Chemother. 42:1098-1104.
31. Schmuck, G., A. Schurmann, and G. Schluter. 1998. Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model. Antimicrob. Agents Chemother. 42:1831-1836.
32. Scotton, P. G., F. Pea, M. Giobbia, M. Baraldo, A. Vaglia, and M. Furlanut. 2001. Cerebrospinal fluid penetration of levofloxacin in patients with spontaneous acute bacterial meningitis. Clin. Infect. Dis. 33:E109-E111.
33. Smith, C. E., B. E. Foleno, J. F. Barrett, and M. B. Frosco. 1997. Assessment of the synergistic interactions of levofloxacin and ampicillin against Enterococcus faecium by the checkerboard agar dilution and time-kill methods. Diagn. Microbiol. Infect. Dis. 27:85-92.
34. Verho, M., V. Malerczyk, D. Damm, and K. H. Lehr. 1996. Pharmacokinetics of levofloxacin in comparison to the racemic mixture of ofloxacin in man. Drug Metab. Drug Interact. 13:57-67.
35. Visalli, M. A., M. R. Jacobs, and P. C. Appelbaum. 1998. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology. Antimicrob. Agents Chemother. 42:953-955.
36. Williams, A. J., and S. Nadel. 2001. Bacterial meningitis: current controversies in approaches to treatment. CNS Drugs 15:909-919.
37. Yamaoka, K., T. Nakagawa, and T. Uno. 1978. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6:165-175.